{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T05:37:42Z","timestamp":1732340262541,"version":"3.28.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"DOI":"10.7759\/cureus.74245","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T16:49:01Z","timestamp":1732294141000},"source":"Crossref","is-referenced-by-count":0,"title":["Increasing Trends in the Pancreatitis Risk With Tumor Necrosis Factor Inhibitor Use"],"prefix":"10.7759","author":[{"given":"Joyce H","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Samarneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey D","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008, 117:244-79. 10.1016\/j.pharmthera.2007.10.001","journal-title":"Pharmacol Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors - state of knowledge","volume":"10","author":"Lis K","year":"2014","unstructured":"Lis K, Kuzawi\u0144ska O, Ba\u0142kowiec-Iskra E. Tumor necrosis factor inhibitors - state of knowledge. Arch Med Sci. 2014, 10:1175-85. 10.5114\/aoms.2014.47827","journal-title":"Arch Med Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221114101","article-title":"Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes","volume":"14","author":"Taylor PC","year":"2022","unstructured":"Taylor PC, Matucci Cerinic M, Alten R, Avouac J, Westhovens R. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. Ther Adv Musculoskelet Dis. 2022, 14:10.1177\/1759720X221114101","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040749","article-title":"Is there a best first line biological\/small molecule in IBD: are we ready for sequencing?","volume":"10","author":"Hahn GD","year":"2022","unstructured":"Hahn GD, Golovics PA, Wetwittayakhlang P, Al Khoury A, Bessissow T, Lakatos PL. Is there a best first line biological\/small molecule in IBD: are we ready for sequencing?. Biomedicines. 2022, 10:749. 10.3390\/biomedicines10040749","journal-title":"Biomedicines"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang DI","year":"2021","unstructured":"Jang DI, Lee AH, Shin HY, et al.. The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci. 2021, 22:2719. 10.3390\/ijms22052719","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1169327","article-title":"Characteristic analysis of adverse reactions of five anti-TNF\u0251 agents: a descriptive analysis from WHO-VigiAccess","volume":"14","author":"Li M","year":"2023","unstructured":"Li M, You R, Su Y, Zhou H, Gong S. Characteristic analysis of adverse reactions of five anti-TNF\u0251 agents: a descriptive analysis from WHO-VigiAccess. Front Pharmacol. 2023, 14:1169327. 10.3389\/fphar.2023.1169327","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2006.07.084","article-title":"Acute pancreatitis and visual impairment after infliximab infusion","volume":"38","author":"Cinquetti M","year":"2006","unstructured":"Cinquetti M, Voltolina C, Bronzini F, Petruzzi S, Lionetti P. Acute pancreatitis and visual impairment after infliximab infusion. Dig Liver Dis. 2006, 38:A114. 10.1016\/j.dld.2006.07.084","journal-title":"Dig Liver Dis"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-201410002-01049","article-title":"Tumor necrosis factor \u03b1 (TNF\u03b1) inhibitor class induced acute pancreatitis","volume":"109","author":"Bhalla R","year":"2014","unstructured":"Bhalla R, Lewis M, Bartel M. Tumor necrosis factor \u03b1 (TNF\u03b1) inhibitor class induced acute pancreatitis. Am J Gastroenterol. 2014, 109:S312-3.","journal-title":"Am J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.22546\/31\/685","article-title":"Acute fulminant drug induced necrotizing pancreatitis in a patient with ankylosing spondylitis treated with etanercept","volume":"76","author":"Miramontes P","year":"2015","unstructured":"Miramontes P, Montilla C, Paniagua IC, Plata A. Acute fulminant drug induced necrotizing pancreatitis in a patient with ankylosing spondylitis treated with etanercept. Galicia Cl\u00edn. 2015, 76:29-30. 10.22546\/31\/685","journal-title":"Galicia Cl\u00edn"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2017.103","article-title":"Tumor necrosis factor alpha inhibitor-induced acute pancreatitis","volume":"4","author":"Werlang ME","year":"2017","unstructured":"Werlang ME, Lewis MD, Bartel MJ. Tumor necrosis factor alpha inhibitor-induced acute pancreatitis. ACG Case Rep J. 2017, 4:e103. 10.14309\/crj.2017.103","journal-title":"ACG Case Rep J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2019.1593783","article-title":"Etanercept - a culprit agent in acute pancreatitis?","volume":"9","author":"Gunawan F","year":"2019","unstructured":"Gunawan F, Fayyaz B, Mihardja TO. Etanercept - a culprit agent in acute pancreatitis?. J Community Hosp Intern Med Perspect. 2019, 9:147-9. 10.1080\/20009666.2019.1593783","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000901948.61075.7b","article-title":"Etanercept: a rare cause of drug-induced pancreatitis","volume":"117","author":"Patel J","year":"2022","unstructured":"Patel J, Butt M. Etanercept: a rare cause of drug-induced pancreatitis. Am J Gastroenterol. 2022, 117:e1226. 10.14309\/01.ajg.0000901948.61075.7b","journal-title":"Am J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcz267","article-title":"Adalimumab-related hypertriglyceridemia and acute pancreatitis","volume":"113","author":"Sahu KK","year":"2020","unstructured":"Sahu KK, Lal A, Mishra AK, Zhang P. Adalimumab-related hypertriglyceridemia and acute pancreatitis. QJM. 2020, 113:298-9. 10.1093\/qjmed\/hcz267","journal-title":"QJM"},{"key":"ref14","article-title":"Drug-induced acute pancreatitis: a review","volume":"15","author":"Jones MR","year":"2015","unstructured":"Jones MR, Hall OM, Kaye AM, Kaye AD. Drug-induced acute pancreatitis: a review. Ochsner J. 2015, 15:45-51.","journal-title":"Ochsner J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s1043-6618(02)00264-5","article-title":"Azathioprine and anti-TNF\u03b1 therapies in Crohn\u2019s disease: a review of pharmacology, clinical efficacy and safety","volume":"47","author":"Arnott ID","year":"2003","unstructured":"Arnott ID, Watts D, Satsangi J. Azathioprine and anti-TNF\u03b1 therapies in Crohn\u2019s disease: a review of pharmacology, clinical efficacy and safety. Pharmacol Res. 2003, 47:1-10. 10.1016\/s1043-6618(02)00264-5","journal-title":"Pharmacol Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000342","article-title":"Concomitant use of azathioprine\/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions","volume":"21","author":"Soh JS","year":"2015","unstructured":"Soh JS, Yun WJ, Kim KJ, et al.. Concomitant use of azathioprine\/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions. Inflamm Bowel Dis. 2015, 21:832-9. 10.1097\/MIB.0000000000000342","journal-title":"Inflamm Bowel Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(80)90689-7\u00a0","article-title":"Drug-induced pancreatitis: a critical review","volume":"78","author":"Mallory A","year":"1980","unstructured":"Mallory A, Kern F Jr. Drug-induced pancreatitis: a critical review. Gastroenterology. 1980, 78:813-20. 10.1016\/0016-5085(80)90689-7\u00a0","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221126353","article-title":"Azathioprine-induced acute pancreatitis in a patient with inflammatory bowel disease","volume":"39","author":"V\u00e1zquez-G\u00f3mez S","year":"2023","unstructured":"V\u00e1zquez-G\u00f3mez S, V\u00e1zquez-G\u00f3mez L. Azathioprine-induced acute pancreatitis in a patient with inflammatory bowel disease. J Pharm Technol. 2023, 39:43-4. 10.1177\/87551225221126353","journal-title":"J Pharm Technol"},{"key":"ref19","unstructured":"FDA Adverse Event Reporting System (FAERS) public dashboard. (2024). Accessed. October 14, 2024: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5772\/50095","article-title":"Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS)","author":"Poluzzi E","year":"2012","unstructured":"Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). Data Mining Applications in Engineering and Medicine. Karahoca A (ed): InTech, 2012. 10.5772\/50095"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3201\/eid1011.040367\u00a0","article-title":"Women and autoimmune diseases","volume":"10","author":"Fairweather D","year":"2004","unstructured":"Fairweather D, Rose NR. Women and autoimmune diseases. Emerg Infect Dis. 2004, 10:2005-11. 10.3201\/eid1011.040367\u00a0","journal-title":"Emerg Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2009.07.009","article-title":"Effects of etanercept on sodium taurocholate-induced acute pancreatitis in rats","volume":"154","author":"Yilmaz M","year":"2009","unstructured":"Yilmaz M, Topsakal S, Herek O, Ozmen O, Sahinduran S, Buyukoglu T, Yonetci N. Effects of etanercept on sodium taurocholate-induced acute pancreatitis in rats. Transl Res. 2009, 154:241-9. 10.1016\/j.trsl.2009.07.009","journal-title":"Transl Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.65.2.204","article-title":"Ameliorative effect of certolizumab on experimentally induced acute necrotic pancreatitis in rats","volume":"65","author":"Kosekli MA","year":"2019","unstructured":"Kosekli MA, Herek O, Ozmen O, Sahinduran S. Ameliorative effect of certolizumab on experimentally induced acute necrotic pancreatitis in rats. Rev Assoc Med Bras (1992). 2019, 65:204-10. 10.1590\/1806-9282.65.2.204","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000002343","article-title":"Certolizumab has favorable efficacy on preventing pancreas and target organs damage in acute pancreatitis","volume":"53","author":"Cirak Z","year":"2024","unstructured":"Cirak Z, Tanoglu A, Yeniceri M, Tanoglu EG, Kaplan M, Sade AG. Certolizumab has favorable efficacy on preventing pancreas and target organs damage in acute pancreatitis. Pancreas. 2024, 53:e588-94. 10.1097\/MPA.0000000000002343","journal-title":"Pancreas"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbz010","article-title":"Precision medicine for acute pancreatitis: current status and future opportunities","volume":"2","author":"Mukherjee R","year":"2019","unstructured":"Mukherjee R, Nunes Q, Huang W, Sutton R. Precision medicine for acute pancreatitis: current status and future opportunities. Precis Clin Med. 2019, 2:81-6. 10.1093\/pcmedi\/pbz010","journal-title":"Precis Clin Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-022-01731-4","article-title":"Immune-related colitis and pancreatitis treated with infliximab","volume":"16","author":"Ohwada S","year":"2023","unstructured":"Ohwada S, Ishigami K, Yokoyama Y, et al.. Immune-related colitis and pancreatitis treated with infliximab. Clin J Gastroenterol. 2023, 16:73-80. 10.1007\/s12328-022-01731-4","journal-title":"Clin J Gastroenterol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.02.016","article-title":"Serious adverse events with infliximab: analysis of spontaneously reported adverse events","volume":"5","author":"Hansen RA","year":"2007","unstructured":"Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007, 5:729-35. 10.1016\/j.cgh.2007.02.016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1731","article-title":"The risk of glioblastoma with TNF inhibitors","volume":"36","author":"Guo M","year":"2016","unstructured":"Guo M, Luo H, Samii A, Etminan M. The risk of glioblastoma with TNF inhibitors. Pharmacotherapy. 2016, 36:449-54. 10.1002\/phar.1731","journal-title":"Pharmacotherapy"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S246328","article-title":"Comparison of adverse event profiles of tumor necrosis factor-alfa inhibitors: analysis of a spontaneous reporting database","volume":"16","author":"Wakabayashi T","year":"2020","unstructured":"Wakabayashi T, Hosohata K, Oyama S, et al.. Comparison of adverse event profiles of tumor necrosis factor-alfa inhibitors: analysis of a spontaneous reporting database. Ther Clin Risk Manag. 2020, 16:741-7. 10.2147\/TCRM.S246328","journal-title":"Ther Clin Risk Manag"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01210-2\u00a0","article-title":"Anti-tumor necrosis factor-alpha therapy and hypoglycemia: a real-world pharmacovigilance analysis","volume":"45","author":"Zhou Y","year":"2022","unstructured":"Zhou Y, Xie W, Wang L, et al.. Anti-tumor necrosis factor-alpha therapy and hypoglycemia: a real-world pharmacovigilance analysis. Drug Saf. 2022, 45:951-9. 10.1007\/s40264-022-01210-2\u00a0","journal-title":"Drug Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/301600-increasing-trends-in-the-pancreatitis-risk-with-tumor-necrosis-factor-inhibitor-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T16:49:04Z","timestamp":1732294144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/301600-increasing-trends-in-the-pancreatitis-risk-with-tumor-necrosis-factor-inhibitor-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.74245","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,22]]}}}